联环药业：控股子公司常乐制药获得美阿沙坦钾片《药品注册证书》

Core Viewpoint - The announcement by Lianhuan Pharmaceutical regarding the approval of its subsidiary Changle Pharmaceutical's drug, Amlodipine Besylate Tablets, indicates progress in the company's product pipeline, although it is not expected to significantly impact recent financial performance [2] Group 1: Company Developments - Lianhuan Pharmaceutical's subsidiary, Changle Pharmaceutical, received the drug registration certificate for Amlodipine Besylate Tablets (40mg/80mg) from the National Medical Products Administration [2] - The research and development investment for Amlodipine Besylate Tablets amounted to approximately RMB 10.99 million [2] - As of the announcement date, Changle Pharmaceutical has obtained 10 production licenses for its products [2] Group 2: Market Impact - The approval of Amlodipine Besylate Tablets is intended for the treatment of primary hypertension in adults [2] - The company anticipates that this approval will not have a significant impact on its recent operating performance [2]